Chlamydia vaccine moves a step closer

Pioneering clinical trial raises hopes of cure for ‘hidden’ sexually transmitted infectionA vaccine to protect against chlamydia has moved closer to becoming reality after a pioneering clinical trial found the treatment to be safe.The vaccine successfully provoked an immune response, boosting levels of antibodies against the chlamydia bacterium in the blood and vaginal fluids.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Chlamydia Sexual health Society Infectious diseases Medical research Microbiology Science Source Type: news

Related Links:

CONCLUSIONS: A tailored practice improvement plan can be envisioned to achieve an optimally functioning STI care continuum. PMID: 31468743 [PubMed - in process]
Source: Journal of the International AIDS Society - Category: Infectious Diseases Tags: J Int AIDS Soc Source Type: research
A potential vaccine for our most common sexually transmitted infection has passed an important early test on the road to availability.
Source: Healthcare News - Category: Pharmaceuticals Authors: Source Type: news
The first-ever human trial of a genital-chlamydia vaccine suggests that it is safe and effective, according to a new study published in the Lancet. U.S. sexually transmitted illness diagnoses have reached new highs for the past four years in a row, and chlamydia is responsible for the bulk of those infections: 1.7 million cases were diagnosed in 2017 alone, according to the U.S. Centers for Disease Control and Prevention, compared to about 550,000 cases of gonorrhea, 40,000 cases of HIV and 30,000 cases of syphilis. Globally, the problem is even more widespread: about 127 million cases were diagnosed in 2016, according to ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized embargoed study Research Source Type: news
The first human trial of a jab to tackle the sexually transmitted disease shows promise, say experts.
Source: BBC News | Health | UK Edition - Category: Consumer Health News Source Type: news
MONDAY, Aug. 12, 2019 -- A vaccine against the sexually transmitted disease chlamydia appears safe and potentially effective, an early trial suggests. The phase 1 study included 35 healthy women. Those who were given injections of two possible...
Source: - Daily MedNews - Category: General Medicine Source Type: news
Chlamydia trachomatis infections are the most prevalent sexually transmitted infections with potentially debilitating sequelae, such as infertility. Mouse models are generally used for vaccine development, to study the immune response and histopathology associated with Chlamydia infection. An important question regarding murine models is the in vivo identification of murine host genes responsible for the elimination of the murine and human Chlamydia strains. RNA sequencing of the Chlamydia muridarum infected BALB/c lung transcriptome revealed that several genes with direct antichlamydial functions were induced at the tiss...
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases (NIAID) today announced awards to establish four Cooperative Research Centers (CRCs) focused on developing vaccines to prevent sexually transmitted infections (STIs). The grants, totaling $41.6 million over five years, will support collaborative, multidisciplinary research on the bacteria that cause syphilis, gonorrhea and chlamydia. At the end of the program, each center is expected to identify at least one candidate vaccine ready for testing in clinical trials.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
Abstract Background &objectives: Limited data are available on the typing of Chlamydia trachomatis in India. Serovars D to K of C. trachomatis are chiefly responsible for urogenital infections. Thus, this study was conducted to determine the distribution of C. trachomatis serovars in patients with urogenital infections and to characterize omp A gene of the detected C. trachomatis isolates by sequence analysis. Presence of other co-infections was also evaluated. Methods: Endocervical swabs were collected from 324 women and urethral swabs/urine were collected from 193 men attending the sexually transmitted ...
Source: The Indian Journal of Medical Research - Category: Biomedical Science Authors: Tags: Indian J Med Res Source Type: research
Discussion A preventative strategy aimed at protecting against HIV infection must block several steps during the earliest stages of infection, avoiding not only the productive infection of primary target cells, but also the viral dissemination toward distal tissues. In both scenarios, antigen-presenting cells residing in different compartments of the female genital mucosa may play a prominent role (7, 9, 24, 35). DC-T cell conjugates represent an optimal milieu for productive HIV infection, which may boost initial viral replication of CD4+ T cells (10, 36). Moreover, uninfected DCs could promote HIV dissemination to drain...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
In this study it was assumed that there was no immunity following resolution of natural infection. The modeling demonstrated that a vaccine of moderate efficacy could have a significant impact on the prevalence of gonorrhea if strategically implemented (23). While encouraging it does, of course, depend on the availability of a vaccine. From Ecological Data to Evidence The epidemiological evidence from Cuba, Brazil, and New Zealand demonstrates that N. meningitidis OMV vaccines are possibly able to provide some broader protection against meningococcal disease (17, 24), particularly in older children and adults (25). These...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
More News: Chlamydia | Clinical Trials | Infectious Diseases | Microbiology | Research | Science | STDs | Vaccines